3.20	Retigabine	Retigabine	Retigabine or ezogabine (USAN), codenamed D-23129, is an anticonvulsant used as a treatment for partial epilepsies. The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline. It was approved by the European Medicines Agency under the trade name Trobalt on March 28, 2011, and by the United States Food and Drug Administration (FDA), under the trade name Potiga, on June 10, 2011.	http://upload.wikimedia.org/wikipedia/commons/thumb/1/13/Retigabine.svg/220px-Retigabine.svg.png
